HES1

Transcription factor HES-1 · Q14469 · HES1 on Sugi Atlas →

769 patent compounds predicted against HES1, 754 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Rutin (SCHEMBL23243)	1.00	2/20
Rutin (SCHEMBL23244)	1.00	2/20
Rutin (SCHEMBL148590)	1.00	2/20
Rutin (SCHEMBL796642)	1.00	2/20
Rutin (SCHEMBL802819)	1.00	2/20
Rutin (SCHEMBL2017898)	1.00	2/20
Rutin (SCHEMBL5580506)	1.00	2/20
Rutin (SCHEMBL5580508)	1.00	2/20
Rutin (SCHEMBL5918715)	1.00	2/20
Rutin (SCHEMBL6552718)	1.00	2/20
Rutin (SCHEMBL8193625)	1.00	2/20
Rutin (SCHEMBL10285592)	1.00	2/20
Rutin (SCHEMBL13696392)	1.00	2/20
Rutin (SCHEMBL13696608)	1.00	2/20
Rutin (SCHEMBL14369486)	1.00	2/20
Rutin (SCHEMBL14952130)	1.00	2/20
Rutin (SCHEMBL15025698)	1.00	2/20
Rutin (SCHEMBL15029221)	1.00	2/20
Rutin (SCHEMBL15263233)	1.00	2/20
Rutin (SCHEMBL15591879)	1.00	2/20

Clinical trials — most relevant to HES1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers	PHASE3	COMPLETED
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis	PHASE2	COMPLETED
A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;	PHASE2	COMPLETED
Development of NIC5-15 in the Treatment of Alzheimer's Disease	PHASE2	COMPLETED
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer	PHASE1/PHASE2	COMPLETED
Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)	PHASE2	COMPLETED
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer	PHASE1/PHASE2	WITHDRAWN
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors	PHASE1	COMPLETED
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	PHASE1	COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors	PHASE1	RECRUITING
Emerging Role of NOTCH-related Long Non-coding RNA(s) as Biomarkers in Liquid Biopsy From Colorectal Cancer Patients	nan	COMPLETED
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma	nan	UNKNOWN
The Role of TBX3 in Human ES Cell Differentiation	nan	WITHDRAWN
Patient-derived Glioma Stem Cell Organoids	nan	ACTIVE_NOT_RECRUITING
Prospective Primary Human Lungcancer Organoids to Predict Treatment Response	nan	COMPLETED
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia	nan	COMPLETED
Genes-in-Action - Hepcidin Regulation of Iron Supplementation	nan	COMPLETED
Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.	nan	UNKNOWN
Effect of Weight Loss Surgery on Stem Cells.	nan	COMPLETED
Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals	nan	COMPLETED
is the Sclerostin Marker of Chronic Periodontitis	nan	COMPLETED
MR Elastography in Intracranial Lesions: Feasibility & Accuracy	nan	ACTIVE_NOT_RECRUITING
Circadian Rhythms and Sleep in Familial DSPS and ASPS	nan	COMPLETED
Genetic Variants of Selected Genes in Colo-Rectal Cancer Patients.	nan	UNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED
Biomarkers for Epilepsy Development and the Effect of Physical Exercise in Children With Autism	nan	COMPLETED
Role of HIF-1α in Skeletal Muscle Aging	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HES1 binder may also engage these)

Protein	Name	Similarity
Q3ZBG4	—	1.000	Q3ZBG4 →
Q04666	—	1.000	Q04666 →
P35428	—	1.000	P35428 →
Q90VV1	—	1.000	Q90VV1 →
Q90Z12	—	1.000	Q90Z12 →
Q8AXV6	—	1.000	Q8AXV6 →
Q9TSZ2	—	1.000	Q9TSZ2 →
Q9WV93	—	0.999	Q9WV93 →
Q8AXV5	—	0.999	Q8AXV5 →
Q2KIN4	—	0.998	Q2KIN4 →
Q8AVU4	—	0.998	Q8AVU4 →
Q6IRB2	—	0.998	Q6IRB2 →
O57337	—	0.996	O57337 →
Q9QUS4	—	0.996	Q9QUS4 →
Q01070	—	0.994	Q01070 →
P14003	—	0.994	P14003 →
Q5PRF9	—	0.994	Q5PRF9 →
P62516	—	0.993	P62516 →
Q5PPM5	—	0.993	Q5PPM5 →
Q26263	—	0.993	Q26263 →
P42571	—	0.993	P42571 →
Q90270	—	0.993	Q90270 →
Q9JJP2	—	0.993	Q9JJP2 →
P13097	—	0.992	P13097 →
P23899	—	0.992	P23899 →
P19359	—	0.992	P19359 →
Q80XS6	—	0.992	Q80XS6 →
Q01068	—	0.992	Q01068 →
P31363	—	0.992	P31363 →
Q7YR49	—	0.992	Q7YR49 →